Hyundai Bioscience Co., Ltd. (048410) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hyundai Bioscience Co., Ltd. (048410:KRX), powered by AI.
- Current Price
- ₩13,450
- P/E Ratio
- -58.7
- Market Cap
- 1.3T
- Sector
- Healthcare
What is the Hyundai Bioscience Co., Ltd. stock price forecast?
Hyundai Bioscience Co., Ltd. is currently trading at ₩13,450. View real-time AI analysis on Alpha Lenz.
What is Hyundai Bioscience Co., Ltd. insider trading activity?
View the latest insider trading data for Hyundai Bioscience Co., Ltd. on Alpha Lenz.
What is Hyundai Bioscience Co., Ltd.'s P/E ratio?
Hyundai Bioscience Co., Ltd.'s P/E ratio is -58.7.
Hyundai Bioscience Co., Ltd.
KRX · 048410“Hyundai Bioscience Co., Ltd. trades at a P/E of -58.7 (undervalued) with modest ROE of -29.5%.”
Ask for details →Company Overview
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Hyundai Bioscience Co., Ltd. trades at a P/E of -58.7 (undervalued) with modest ROE of -29.5%.”
Ask for details →Frequently Asked Questions
Hyundai Bioscience Co., Ltd. (ticker: 048410) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 54 employees. Market cap is $1.3T.
The current price is ₩13,450 with a P/E ratio of -58.66x and P/B of 11.72x.
ROE is -29.47% and operating margin is -516.32%. Annual revenue is $3.5B.